References
- De Milliano, P. A., de Groot, A. C., Tijssen, J. G., eck-Smit, B. L., Van Zwieten, P. A., Lie, K. I. (2002). Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J 144:E3.
- Department of Health Organization, Taiwan (DOH). (2000). Guideline for the Nonclinical Pharmacology/Toxicology Studies for Medicinal Products Applications, 3rd ed. Taiwan, ROC.
- Eichhorn, E. J., McGhie, A. L., Bedotto, J. B., Corbett, J. R., Malloy, C. R., Hatfield, B. A., et al. (1991). Effects of bucindolo on neurohormonal activation in congestive heart failure. Am J Cardiol 67:67–73.
- Erol-Yilmaz, A., Verberne, H. J., Schrama, T. A., Hrudova, J., De Winter, R. J., Van Eck-Smit, B. L., et al. (2005). Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 28:304–310.
- FDA. (1996). Single Dose Acute Toxicity Testing for Pharmaceuticals. Silver Spring, Maryland, USA: U.S. Food and Drug Administration.
- He, Y., Das, B., Baruchel, S., Kumar, P., Wiebe, L., Reilly, R. M. (2004). Meta-[123I]iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage. Nucl Med Commun 25:1125–1130.
- Kasama, S., Toyama, T., Sumino, H., Nakazawa, M., Matsumoto, N., Sato, Y., et al. (2008). Prognostic value of serial cardiac 123-I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 49:907–914.
- Kasama, S., Toyama, T., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., et al. (2002). Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 43:1279–1285.
- Kasama, S., Toyama, T., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., et al. (2003). Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 41:574–581.
- Kalliomäki, T., Hill, R. P. (2004). Effects of tumour acidification with glucose+MIBG on the spontaneous metastatic potential of two murine cell lines. Br J Cancer 90:1842–1849.
- Patel, A. D., Iskandrian, A. E. (2002). MIBG imaging. J Nucl Cardiol 9:75–94.
- Shapiro, B., Copp, J. E., Sisson, J. C., et al. (1985). Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585.
- Somsen, G. A., van Vlies, B. de, Milliano, P. A., Borm, J. J., van Royen, E. A., Endert, E., et al. (1996). Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 76:218–222.
- Takatsu, H., Nishida, H., Matsuo, H., Watanabe, S., Nagashima, K., Wada, H., et al. (2000). Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 41:71–77.
- Wieland, D. M., Wu, J., Brown, L. E., et al. (1980). Radiolabeled adrenergic neuron-blocking agent: adrenomedullary imaging with 131I-metaiodobenzylguanidine. J Nucl Med 21:349–353.
- Wieland, D. M., Brown, L. E., Rogers, W. L., Worthington, K. C., Wu, J. L., Clinthorne, N. H., et al. (1981). Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 22:22–31.